Open AccessEfficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection
Author(s) -
Thomas Birch,
Yoav Golan,
Giuliano Rizzardini,
Erin Jensen,
Lori Gabryelski,
Dalya Güriş,
Marcus Dörr
Publication year - 2018
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dky182
Subject(s) - clostridium difficile , microbiology and biotechnology , medicine , clostridium , c difficile , biology , bacteria , antibiotics , genetics
The fully human monoclonal antibody bezlotoxumab binds Clostridioides (Clostridium) difficile toxin B and reduces recurrence rates in patients with C. difficile infection (CDI) receiving antibacterial treatment for a primary or recurrent episode.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom